Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Syngene is a science company that does lab research and drug development work for other companies that don't want to build their own labs.
Syngene International is a contract research organization, which is a fancy way of saying it does science for hire. If a drug company has an idea for a new medicine but doesn't want to spend years and a fortune building its own labs and hiring hundreds of PhDs, it can hand the work to Syngene instead. Syngene runs the experiments, tests the compounds, and helps move a molecule from a sketch on a whiteboard toward something a regulator might actually approve. Its customers are the big players: global pharmaceutical giants, biotech startups, and animal health and consumer goods companies. Headquartered in Bengaluru, India, the company was originally spun out of Biocon back in the 1990s as a place where Western drugmakers could get high-quality science done at a lower cost than at home.
Think of it as the kitchen that cooks for many restaurants. Syngene doesn't sell its own dish. It takes orders from lots of companies, cooks carefully to each one's recipe, and hands back the finished plate. The company makes money mainly through long-term contracts, and its biggest and most famous client is Bristol Myers Squibb, which has had a dedicated research center inside Syngene for years. That kind of deal matters because it's sticky: once a client's scientists are embedded in your labs and your systems, switching is painful. Beyond discovery chemistry, Syngene has pushed into biologics (large molecules made in living cells), and it also runs a growing manufacturing arm that makes medicines for other companies, including a facility in Mangalore that serves global markets.
The business has matured from a scrappy spin-off into a serious player with annual revenue of roughly $400 to $450 million, growing at a healthy clip. For years, its story was simple: more clients, more science, more revenue. Now the interesting tension is whether it can keep moving up the value chain, from running experiments to actually making finished drugs, where the margins are fatter but the competition and regulatory scrutiny are tougher. The company spends heavily on new labs and capabilities, which is the classic contract-research trade-off: you have to build it before you can bill for it. Watch the Bristol Myers Squibb relationship, the biologics push, and whether the newer manufacturing bets start pulling their weight.
Saved answer · last researched 11 Oct 2026